ImmunoVest is a Singapore based biotechnology company focusing on the clinical development and clinical trial of NK cells and Car-T for cancer treatments. The company's business model is centred around developing innovative, cutting-edge therapies that have the potential to revolutionize the treatment of cancer.
The company's intellectual property includes patented microcarriers, pluripotency markers, additives, and safety markers. These patents allow for the formation of microcarriers-stem cell complexes in 3D culture, differentiation between undifferentiated and differentiated stem cells, maintenance of cell stability in long-term culture, and the removal of undifferentiated ESC and cancer stem cells.
Company Details
- Founded
- -
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://immunovest.com/
- Keywords
- Yardeni Group.
Immunovest Questions
Immunovest's website is https://immunovest.com/
Immunovest's LinkedIn profile is https://www.linkedin.com/company/immunovest
Immunovest's industry is
Biotechnology Research
Immunovest's top competitors are
The Zenventure,
Go-Dx Corporation Ltd,
Cannioasis,
Betalife,
Sigmawave Ai,
Innocellular,
Ec2 Media,
Beany Digital,
Yardeni Group,
Motics.
Immunovest's categories are Biotechnology Research
Immunovest's founding year is 2023
